NCT00750932

Completed

Biodistribution of Neutrophile Proteases in the Sputum of Pa...

University Hospital, Tours Source

Compare

Other study identifiers

Sponsor study identifier

AOHP07-PD Pro-Muco

Secondary identifiers

DGS2007-0295

N° ID RCB:2007-A00511-52

CPP: 2007-R17

Study Type

observational

Actual enrollment (reported)

52

Locations

1 country

Sites

1

Timeline

Study Start

January 2008

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

January 2012

Actual (reported)

Study Completion

January 2012

Actual (reported)

Brief Summary

The purpose of the proposed project is to characterize the neutrophile proteases which participate in the chronic inflammatory phenomenon associated with the cystic fibrosis and which are responsible for the degradation of the lung tissue. The respiratory failure which results from it is one of main causes of the fatal evolution of this pathology but the anti-inflammatory therapies based on the use of antiproteases targeting specifically the soluble elastase did not end, until now, in the hoped results. The identification of the other noxious targets is a crucial element to give new orientations to the anti-inflammatory strategies based on the administration of antiproteases which remain a promising way.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 52 participants
Study completion date: January 2012
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
January 2008
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
September 10, 2008
Actual (reported)
First Posted
September 11, 2008
Actual (reported)
Primary Completion
January 2012
Actual (reported)
Study Completion
January 2012
Actual (reported)

Last Updated: February 27, 2017
Status Verified: February 2017
Last Update Submitted: February 23, 2017

Conditions

Cystic Fibrosis

Study Arms (3)

T

Control

M

Minor with cystic fibrosis

A

Adult with cystic fibrosis

Eligibility Criteria

Age6 Years+

Sexall

Healthy VolunteersYes

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Adults and children with cystic fibrosis

You may qualify if:

Man /woman older than 18 years (for adult and group)

Sponsors & Collaborators

University Hospital, Tours
Otherlead

Study Sites (1)

CHRU de Tours

Tours, 37044, France

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood Sputum

MeSH Terms

Conditions

Cystic Fibrosis

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System DiseasesLung DiseasesRespiratory Tract DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesInfant, Newborn, Diseases

Study Officials

Patrice DIOT, PHD
Tours Hospital
PRINCIPAL INVESTIGATOR

Enrollment

52 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 10, 2008

First Posted

September 11, 2008

Study Start

January 2008

Date type not reported

This date has not been verified as actual or estimated.

NCT00792194

Improvement of Aerobic Capacity in Cystic Fibrosis Patients With a One-year Home Training Period

Not ApplicableCompleted

NCT00391703

Assessment of Quadriceps Muscle Electrostimulation Used in Patients Suffering From Cystic Fibrosis

Not ApplicableTerminated

NCT06457451

Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial

Not ApplicableRecruiting

NCT01285895

Needs in Education for Pulmonary or Cardiopulmonary Transplanted Cystic Fibrosis Patients

Completed

NCT00458341

A Study of Ataluren in Pediatric Participants With Cystic Fibrosis

Phase 2Completed

NCT01285882

Representations of Transplantation in Patients and in Health Care Professionals

Completed

Child aged 6 to 18 years (for child group)

Suffering from cystic fibrosis in stable condition, ie not having presented thrust acute attack of the broncho-pulmonary or hospitalization for treatment of his illness during the previous 2 weeks

You may not qualify if:

colonized by Burkholderia cepacia ou Stenotrophomonas maltophilia
non smoker (control group)
Without history or respiratory respiratory disease known (control group)

Contact the study team to confirm eligibility.

Primary Completion

January 2012

Actual (reported)

Study Completion

January 2012

Actual (reported)

Last Updated

February 27, 2017

Record last verified: 2017-02

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00750932
Data provider: ClinicalTrials.gov
Source updated: 2017-02-27
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:31:00 UTC

Locations

FR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Study Arms (3)

T

M

A

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations